Cyclic Peptides in Drug Discovery: From Cyclosporine to Next-Generation Oral Macrocycles
The Renaissance of Macrocyclic Therapeutics
Cyclic peptides occupy a unique chemical space — larger than traditional small molecules (MW < 500 Da, Lipinski rule-of-five compliant) yet smaller than biologics (MW > 5,000 Da). This “middle space” (MW 500–2,000 Da) enables cyclic peptides to bind large, flat protein surfaces while potentially retaining oral bioavailability — a combination neither conventional small molecules nor antibodies can achieve.
The clinical validation is robust: over 40 cyclic peptide drugs have received FDA approval, generating combined annual revenues exceeding $6 billion (Driggers et al., Nature Reviews Drug Discovery, 2008).
Structural Basis for Enhanced Pharmacological Properties
Conformational Restriction
Cyclization reduces the conformational degrees of freedom from ~3N (where N is the number of rotatable bonds) to a much smaller ensemble of accessible conformations. This pre-organization provides:
- Entropic advantage in target binding (ΔΔSbinding ≈ 5–15 cal/mol·K)
- Enhanced selectivity — the rigid scaffold is less likely to adopt conformations that bind off-target proteins
- Predictable SAR — structure-activity relationships are more interpretable when the backbone geometry is constrained
Proteolytic Stability
Exopeptidases (aminopeptidases, carboxypeptidases) — responsible for >80% of peptide degradation in serum — require a free N- or C-terminus. Head-to-tail backbone cyclization eliminates both termini, conferring 10–100× improved serum stability. Endopeptidase resistance is further enhanced by incorporating D-amino acids or N-methylation at susceptible cleavage sites (White & Bhatt, Journal of Medicinal Chemistry, 2022).
Membrane Permeability and Oral Bioavailability
The discovery that Cyclosporine A (CsA) achieves oral bioavailability (~30%) despite violating all Lipinski rules (MW 1,203, 7 H-bond donors) revolutionized thinking about macrocyclic drug design. Key structural features enabling CsA's permeability include:
- N-methylation of 7/11 amide bonds — shielding H-bond donors from the lipid bilayer
- Intramolecular hydrogen bonding — a network of transannular H-bonds creates a “closed” conformation that buries polar groups in nonpolar solvents (the “chameleonic” property)
- Conformational flexibility — the ability to switch between “open” (aqueous) and “closed” (membrane) states
Modern Cyclization Chemistries
| Chemistry | Bond Formed | Key Reagents | Advantages |
|---|---|---|---|
| Head-to-tail (backbone) | Amide | PyBOP, DEPBT in high dilution | Most natural, removes termini |
| Lactam bridge | Amide (Lys-Asp/Glu) | On-resin, orthogonal protection (Alloc/Allyl) | Side-chain constraint, helicity |
| Disulfide | S-S (Cys-Cys) | DMSO oxidation, I₂, or air | Reversible, biomimetic |
| Thioether | C-S | Chloroacetyl + Cys alkylation | Stable, irreversible |
| CuAAC “click” | 1,2,3-Triazole | Azidoalanine + propargylglycine, CuSO₄/ascorbate | Bioorthogonal, regioselective |
| RCM stapling | C=C (olefin) | Grubbs II catalyst | Hydrocarbon bridge, lipophilic |
Case Studies: FDA-Approved Cyclic Peptides
Daptomycin (Cubicin®)
A 13-residue lipocyclic peptide antibiotic with a unique mechanism: it inserts into Gram-positive bacterial membranes in a Ca²⁺-dependent manner, forming oligomeric pores that depolarize the membrane. Its 10-residue macrolactone ring (Thr-Trp cyclization) provides the structural rigidity essential for membrane insertion. Annual sales exceed $1 billion.
Octreotide (Sandostatin®)
An 8-residue somatostatin analog with a disulfide bridge (Cys2-Cys7) that constrains the pharmacophoric β-turn. Cyclization extends the half-life from ~3 minutes (native somatostatin) to ~90 minutes — a 30-fold improvement that enables clinical utility in acromegaly and neuroendocrine tumors.
Our Cyclic Peptide Capabilities
Boston Molecules provides end-to-end custom cyclic peptide synthesis services, from sequence design consultation through purification and characterization. Our capabilities include all cyclization chemistries listed above, with particular expertise in multi-disulfide peptides (up to 3 bridges) and N-methylated macrocycles for oral delivery programs.
References
- Driggers, E.M. et al. “The exploration of macrocycles for drug discovery.” Nature Reviews Drug Discovery 7, 608–624 (2008)
- White, C.J. & Bhatt, D.P. “Cyclic peptide drug design and optimization.” Journal of Medicinal Chemistry 65, 11270–11290 (2022)
- Passioura, T. et al. “Selection-based discovery of druglike macrocyclic peptides.” Annual Review of Biochemistry 83, 727–752 (2014)
- Rezai, T. et al. “Conformational flexibility, hydrogen bonding, and passive membrane permeability.” Journal of the American Chemical Society 128, 14073–14080 (2006)
Leave a Reply